To the Editor:
A 40-year-old woman with a history of stage IIIC ovarian cancer presented with progressing abdominal erythema and pain of 1 month’s duration. She had been diagnosed 4 years prior with grade 3, poorly differentiated papillary serous carcinoma involving the bilateral ovaries, uterine tubes, uterus, and omentum with lymphovascular invasion. She underwent tumor resection and debulking followed by paclitaxel plus platinum-based chemotherapy. The cancer recurred 2 years later with carcinomatous ascites. She declined chemotherapy but underwent therapeutic paracentesis.

One month prior to presentation, the patient developed a small, tender, erythematous patch on the abdomen. Her primary physician started her on cephalaxin for presumed cellulitis without improvement. The erythema continued to spread on the abdomen with worsening pain, which prompted her presentation to the emergency department. She was admitted and started on intravenous vancomycin.

On admission to the hospital, the patient was cachexic and afebrile with a white blood cell count of 10,400/µL (reference range, 4500–11,000/µL). Physical examination revealed a well-demarcated, 15×20-cm, erythematous, blanchable, indurated plaque in the periumbilical region (Figure 1). The plaque was tender to palpation with guarding but no increased warmth. Punch biopsies of the abdominal skin revealed carcinoma within the lymphatic channels in the deep dermis and dilated lymphatics throughout the overlying dermis (Figure 2). These findings were diagnostic for carcinoma erysipeloides. Tissue and blood cultures were negative for bacterial, fungal, or mycobacterial growth. Vancomycin was discontinued,

FIGURE 1. A well-demarcated, 15×20-cm, erythematous, blanching, indurated plaque on the periumbilical area that was diagnosed as carcinoma erysipeloides.

PRACTICE POINTS
- Carcinoma erysipeloides is a rare cutaneous marker of metastatic ovarian cancer.
- Clinicians should be aware of carcinoma erysipeloides in ovarian cancer and maintain a low threshold for biopsy for accurate diagnosis and management planning.

Carcinoma Erysipeloides of Papillary Serous Ovarian Cancer Mimicking Cellulitis of the Abdominal Wall

Vivian Wong, MD, PhD; Carol E. Cheng, MD; Steven R. Tahan, MD; Caroline C. Kim, MD

Dr. Wong is from the Department of Dermatology, Brown University, Providence, Rhode Island. Dr. Cheng is from the Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California Los Angeles. Drs. Tahan and Kim are from Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dr. Tahan is from the Department of Pathology and Dr. Kim is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Caroline C. Kim, MD, Beth Israel Deaconess Medical Center, Department of Dermatology, 330 Brookline Ave, Shapiro 2, Boston, MA 02215 (ckim3@bidmc.harvard.edu).

Copyright Cutis 2018. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.
and she was discharged with pain medication. She declined chemotherapy due to the potential side effects and elected to continue symptomatic management with palliative paracentesis. After she was discharged, she underwent a tunneled pleural catheterization for recurrent malignant pleural effusions.

Carcinoma erysipeloides is a rare cutaneous metastasis secondary to internal malignancy that presents as well-demarcated areas of erythema and is sometimes misdiagnosed as cellulitis or erysipelas. Histology is notable for lymphovascular congestion without inflammation. Carcinoma erysipeloides most commonly is associated with breast cancer, but it also has been described in cancers of the prostate, larynx, stomach, lungs, thyroid, parotid gland, fallopian tubes, cervix, pancreas, and metastatic melanoma.1-5 While the pathogenesis of carcinoma erysipeloides is poorly understood, it is thought to occur by direct spread of tumor cells from the lymph nodes to the cutaneous lymphatics, causing obstruction and edema.

Ovarian cancer has the highest mortality of all gynecologic cancers and often is associated with delayed diagnosis. Cutaneous metastasis is a late manifestation often presenting as subcutaneous nodules.5,7 Carcinoma erysipeloides is an even rarer presentation of ovarian cancer, with a poor prognosis and a median survival of 18 months. A PubMed search of articles indexed for MEDLINE using the term carcinoma erysipeloides revealed 9 cases of carcinoma erysipeloides from ovarian cancer: 1 describing erythematous papules, plaques, and zosteriform vesicles on the upper thighs to the lower abdomen,9 and 8 describing erythematous plaques on the breasts.8,10 We report a case of carcinoma erysipeloides associated with stage IIIc ovarian cancer localized to the abdominal wall mimicking cellulitis. Our report reminds clinicians of this important diagnosis in ovarian cancer and of the importance of a skin biopsy to expedite a definitive diagnosis. Immunohistochemistry using ovarian tumor markers (eg, paired-box gene 8, cancer antigen 125) is an additional tool to accurately identify malignant cells in skin biopsy.8,10 Once diagnosed, primary treatment for carcinoma erysipeloides is treatment of the underlying malignancy.

REFERENCES


FIGURE 2. A punch biopsy of a carcinoma erysipeloides revealed carcinoma cells morphologically consistent with papillary serous carcinoma of the ovaries present within the lymphatic channels in the deep dermis, as seen in the inset (single arrows). Lymphatic channels in the overlying dermis were dilated (red arrows), suggesting lymphatic obstruction (H&E, original magnification ×20; inset, original magnification ×200).